SLC35F2 Activators
SLC35F2 Activators refers to a group of compounds that have been identified for their ability to modulate the activity of SLC35F2, which is a member of the solute carrier (SLC) family of transport proteins. SLC35F2, also known as UDP-galactose transporter-related protein 2 (UGTrel2), plays a crucial role in cellular processes related to the transportation of UDP-galactose, a nucleotide sugar that serves as an essential substrate for glycosylation reactions. Glycosylation is a post-translational modification process that involves the attachment of sugar molecules to proteins and lipids, and it is critical for the proper functioning of various biological systems.
The activation of SLC35F2 by these compounds is believed to enhance the transport of UDP-galactose across cellular membranes, facilitating its availability for glycosylation reactions within the cell. While the precise mechanisms by which SLC35F2 activators interact with the transporter are still under investigation, it is evident that these compounds hold promise in influencing glycosylation pathways and potentially impacting various cellular functions. The study of SLC35F2 activators is of particular interest to researchers in the fields of cell biology and biochemistry, as glycosylation plays a fundamental role in cell signaling, immune response regulation, and protein stability.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits Golgi alpha-mannosidase II, resulting in the accumulation of misprocessed glycoproteins. This could indirectly increase the demand for SLC35F2 activity as cells attempt to correct glycosylation defects. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is an inhibitor of glucosidases, which may result in enhanced SLC35F2 activity due to the increased demand for proper glycoprotein folding and maturation in the Golgi apparatus. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine inhibits mannosidase I in the ER, leading to misfolded glycoproteins that stimulate the UPR, potentially enhancing SLC35F2 activity to meet the increased needs for glycosylation correction. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidase I and II, potentially increasing the functional demand for SLC35F2 as part of the cellular response to restore glycoprotein processing efficiency. | ||||||